<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02063607</url>
  </required_header>
  <id_info>
    <org_study_id>NNG01</org_study_id>
    <nct_id>NCT02063607</nct_id>
  </id_info>
  <brief_title>The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients</brief_title>
  <official_title>The Phase 1a/1b Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanogen Pharmaceutical Biotechnology Joint Stock Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanogen Pharmaceutical Biotechnology Joint Stock Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, dose ranging, phase1a/1b clinical trial to study the safety,&#xD;
      Pharmacokinetics and Pharmacodynamics of Peglamda 60, 120, 180 and 240 mcg in healthy&#xD;
      volunteers and antiviral activity of once weekly Peglamda administration in combination with&#xD;
      daily Ribavirin in Hepatitis C naive patients up to 4 weeks period. The objective of the&#xD;
      study to establish safety, PK/PD data on healthy subjects and preliminary efficacy and safety&#xD;
      in Hepatitis C naive patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve (AUC 0-336)</measure>
    <time_frame>0, 6, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264 and 336 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Patients achieving Rapid Virological Response (RVR)</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with incidence of adverse events</measure>
    <time_frame>15 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Peginterferon alfa 2a</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Peginterferon alfa 2a 180 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peginterferon Lambda</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peginterferon Lambda 60,120,180 and 240 mcg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Peginterferon lambda</intervention_name>
    <arm_group_label>Peginterferon Lambda</arm_group_label>
    <arm_group_label>Peginterferon alfa 2a</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Phase 1a: The subjects who are willing to participate in Phase 1a study must meet ALL of&#xD;
        the following inclusion criteria:&#xD;
&#xD;
          1. Volunteers (male and female) between the ages of 18-45&#xD;
&#xD;
          2. Women have a negative pregnancy test result at the time of study.&#xD;
&#xD;
          3. Clinical examination and result laboratory for 7 days before starting the trial must&#xD;
             be inside the normal range.&#xD;
&#xD;
          4. Currently not following any treatment regimen (except for using the oral&#xD;
             contraceptive).&#xD;
&#xD;
          5. Body mass index is between the range and / or not 25% difference compared to the&#xD;
             normal BMI (Appendix 6).&#xD;
&#xD;
          6. Be able to comply with protocol and exchange information effectively with the&#xD;
             researchers, agree on the written informed consent to participate in the clinical&#xD;
             trial&#xD;
&#xD;
        Phase 1b: Subjects willing to participate into the phase 1b study must meet ALL of the&#xD;
        following inclusion criteria:&#xD;
&#xD;
          1. Patients with chronic hepatitis C (male and female).&#xD;
&#xD;
          2. Ages between 18 - 65 years old.&#xD;
&#xD;
          3. Female patient (or female partners of the male patients) with negative pregnancy test&#xD;
             results and/or apply effective contraception if still having sex during the study and&#xD;
             for 6 months after using the last dose of Ribavirin.&#xD;
&#xD;
          4. No previous treatment with IFN or IFN treatment with rapid viral response or already&#xD;
             have completely viral response but leave the treatment early.&#xD;
&#xD;
          5. HCV-RNA levels in serum &gt; 80 IU / mL.&#xD;
&#xD;
          6. The haematological and biochemical (except ALT / AST) parameters must be within normal&#xD;
             limits.&#xD;
&#xD;
          7. Body weight in the normal range of 25% difference compared to the normal BMI (Appendix&#xD;
             6)&#xD;
&#xD;
          8. Be able to comply with protocol and exchange information effectively with the&#xD;
             researchers, agree on the written informed consent to participate in the clinical&#xD;
             trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Phase 1a: Subjects with at least 1 of the following exclusion criteria are considered&#xD;
        ineligible to participate in Phase 1a study:&#xD;
&#xD;
          1. With a history of drug abuse, alcohol or drug using within 1 year before taking part&#xD;
             in the clinical trial. AUDIT-C scale (WHO) will be used to assess the use of alcohol.&#xD;
             The score ≥ 4 in men or ≥ 3 in women are considered as alcoholics.&#xD;
&#xD;
          2. History of depression&#xD;
&#xD;
          3. History of chronic diseases related to the respiratory system, cardiovascular,&#xD;
             gastrointestinal, malignant disease affecting to the function of the organ systems.&#xD;
             Having any interferon or antiviral therapy within 4 months before the trial&#xD;
&#xD;
          4. Participate in any clinical trial within 3 months prior the testing&#xD;
&#xD;
          5. Use of any drug in the last period of relatively positive test which last&#xD;
             approximately 6 times the half-life of the drug.&#xD;
&#xD;
          6. Blood donor with more than 400 mL of blood within 3 months prior the testing&#xD;
&#xD;
          7. Influenza infection or cold symptoms within 2 weeks before the trial&#xD;
&#xD;
          8. Having positive tests of HBV, HCV or HIV&#xD;
&#xD;
          9. Breastfeeding women&#xD;
&#xD;
        Phase 1b: Subjects with at least 1 of the following exclusion criteria are considered&#xD;
        ineligible to participate in Phase 1b study:&#xD;
&#xD;
          1. Co-infection with hepatitis B and/or HIV.&#xD;
&#xD;
          2. Hepatic Impairment&#xD;
&#xD;
          3. Cirrhosis&#xD;
&#xD;
          4. Positive tests with antibody of Peginterferon lambda 1 and Peginterferon alpha 2a.&#xD;
&#xD;
          5. History of chronic diseases related to the respiratory system, cardiovascular,&#xD;
             gastrointestinal, malignant disease affecting to the function of the organ systems.&#xD;
&#xD;
          6. A history of immune disorders (eg, inflammatory bowel disease, hemorrhagic&#xD;
             thrombocythemia, lupus erythematosus, autoimmune hemolytic anemia, autoimmune disease,&#xD;
             scleroderma, severe psoriasis, arthritis rheumatoid ...)&#xD;
&#xD;
          7. A history of severe mental illness, especially depression, especially the serious&#xD;
             neurological condition determined as depression or serious psychological disorders,&#xD;
             suicidal intention, or being hospitalized for mental illness, or having 1 phase of&#xD;
             impaired function due to neuropathy.&#xD;
&#xD;
          8. A history of severe epilepsy or using antiepileptic drugs.&#xD;
&#xD;
          9. A history of using anti-cancer agents (including radiation therapy) or immunotherapy&#xD;
             (including systematic corticosteroids) within 6 months before using the first testing&#xD;
             dose or the patient may be in need of this treatment during the trial&#xD;
&#xD;
         10. History of organ transplants with the presence of the graft function.&#xD;
&#xD;
         11. Evidence of alcohol or drugs abuse within 1 year before the trial. AUDIT scale - C&#xD;
             will be used to assess the use of alcohol. The score ≥ 4 in men or ≥ 3 in women are&#xD;
             considered as alcoholics&#xD;
&#xD;
         12. History or evidence of severe disease or any other condition based on the investigator&#xD;
             assessment that the subject may not be suitable for this study.&#xD;
&#xD;
         13. Breastfeeding women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr.Chinh Trong Nguyen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Military 108 Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Military 108 Hospital</name>
      <address>
        <city>Hanoi</city>
        <zip>10000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>February 11, 2014</study_first_submitted>
  <study_first_submitted_qc>February 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2014</study_first_posted>
  <last_update_submitted>December 13, 2016</last_update_submitted>
  <last_update_submitted_qc>December 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

